Agilent Receives Approval for First PD-L1 Companion Diagnostic in China
Agilent Technologies, Inc. (A)
Last agilent technologies, inc. earnings: 2/18 04:05 pm
Check Earnings Report
US:NYSE Investor Relations:
investor.agilent.com
Company Research
Source: Business Wire
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the National Medical Products Administration (NMPA, formerly the China Food and Drug Administration) has approved its PD-L1 IHC 22C3 pharmDx assay for use in China.The assay is now approved as a companion diagnostic to identify patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (tumor proportion score [TPS] 1%) for first-line treatment with single-agent KEYTRUDA, an anti-PD-1 therapy manufactured by Merck & Co., Inc. Kenilworth, NJ, U.S.A.Lung cancer accounts for 20% of all cancer deaths in China and is the leading cause of cancer death there1. NMPA approved the assay to identify advanced NSCLC patients whose tumors express PD-L1 Tumor Proportion Score (TPS) = 1% for first-line treatment with KEYTRUDA monotherapy. KEYTRUDA, as monotherapy, recently received NMPA approval for first-line treatment of patients with locally advanced or
Show less
Read more
Impact Snapshot
Event Time:
A
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
A alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
A alerts
High impacting Agilent Technologies, Inc. news events
Weekly update
A roundup of the hottest topics
A
News
- Mission Bio's New Translocation Analysis Offers Insights into Critical Safety Assessment for Gene-Edited Cell Products [Yahoo! Finance]Yahoo! Finance
- Single Nucleotide Polymorphism Genotyping Market Global Industry Analysis & Forecast 2018-2028: Pharmaceutical Development Accelerates SNP Genotyping Utilization [Yahoo! Finance]Yahoo! Finance
- Expansion of Organic and Sustainable Agriculture Catapults the Pesticide Detection Market; FMI Analysts Predict Market Valuation to Surpass US$ 3,049.50 million by 2034 [Yahoo! Finance]Yahoo! Finance
- Companion Diagnostics Market is Expected to Reach $13.6 billion | MarketsandMarkets™ [Yahoo! Finance]Yahoo! Finance
- Peptide and Oligonucleotide CDMO Market Size, Outlook: Analysing the 11.5% CAGR and USD 7.40 Billion Projection by 2033 [Yahoo! Finance]Yahoo! Finance
A
Earnings
- 2/27/24 - Beat
A
Sec Filings
- 4/10/24 - Form SC
- 3/27/24 - Form 4
- 3/25/24 - Form 144
- A's page on the SEC website